Introduction"
Previously 2'-deoxyribonucleoside cyanoboranes and phosphate-boronated nucleotides were shown to be hypolipidemic agents in rodents at 8 mg/kg/day ip and orally [i] . In rats the cholesterol levels of VLDL and LDL fractions were reduced and the HDL-cholesterol content was significantly increased with reductions of both serum cholesterol and triglyceride levels after 14 days at 8 mg/kg/day of these boronated deoxyribonucleosides. These boronated nucleosides and nucleotides were shown to be safe for therapeutic use [2] .
We have now expanded the types of nucleosides with boron substitutions at different nitrogen moieties. The current investigation is an effort to establish their hypolipidemic activity in mice and rats at 8 mg/kg/day.
Methods:
Source of materials:
All of the compounds have previously been synthesized and the chemical and physical characteristics reported [3] [4] [5] . All In vitro enzymatic studies were performed using 10% homogenates of liver from normalipidemic Sprague Dawley male rats (-230g [14] and adenosine triphosphate dependent citrate lyase activities [15] were determined spectrophotometrically at 540 Small intestinal mucosa and aorta wall triglyceride levels were reduced as was aorta wall phospholipids and protein content. 
Discussion
The boronated nucleosides were potent hypolipidemic agents in rodents at 8 mg/kg/day both by po and ip administration. The N boronated guanosine derivative 3 as well as 3'-aminocyanoborane dideoxythymidine 6, the 
